The effects of the type V phosphodiesterase (PDE V) inhibitors, MBCQ, zaprinast and dipyridamole, on the relationship between relaxation and cyclic nucleotide content were investigated in rat ileal smooth muscle. Each of MBCQ (0.01-10 µM), zaprinast (0.1-100 µM) and dipyridamole (0.1-100 µM) inhibited carbachol (CCh; 10 µM)-induced contractions in a concentration-dependent manner. When compared with the concentrations of these agents producing 50% relaxation (IC50) of CCh-induced contraction, MBCQ was 14-20 fold more potent than the other agents. The inhibitory potency of these agents against high K + (65 mM KCl)-induced contractions were similar to that for CCh. MBCQ (1, 10 µM) did not significantly increase the cGMP content above control levels in the presence of CCh (10 µM). Both Zaprinast (1-100 µM) and dipyridamole (1-100 µM) increased the cGMP content of smooth muscle preparations in a concentration-dependent manner. There was a positive correlation between the inhibition of the CCh-induced contraction and the increase in cGMP content elicited by zaprinast and dipyridamole (zaprinast; r=0.72, P<0.05, dipyridamole; r=0.92, P<0.05). However, MBCQ at a concentration which induced a medium-sized relaxation did not significantly increase the cGMP content. Neither MBCQ, zaprinast nor dipyridamole significantly increased the cAMP content of the preparations above control. In summary, it is suggested that the inhibition of CCh-induced contractions by zaprinast and dipyridamole involves increases in cGMP content via inhibition of PDE V. However the inhibition of CCh-induced contraction by MBCQ may not involve cyclic nucleotides in rat ileal smooth muscle.
Introduction
Cyclic nucleotides are important secondary messengers and have been associated with smooth muscle relaxation (Diamond, 1978) . They are synthesized by either adenyl cyclase or guanylyl cyclase and degraded by phosphodiesterase (PDE). Currently, PDEs are classified into several families (Beavo, 1995; Fawcett et al., 2000; Yuasa et al., 2000) and selective PDE inhibitors have been found (Beavo and Reifsnyder, 1990) . Selective PDE (type I-type V) inhibitors regulating the contractility of vascular smooth muscle (Polson and Strada, 1996) , tracheal smooth muscle (Raeburn and Advenier, 1995) and intestinal smooth muscle (Barnette et al., 1993; Tomkinson and Raeburn, 1996) have been reported. Additionally, it has been reported that PDE V inhibitors cause more marked relaxation in endothelium-intact vascular muscle than that in endothelium-denuded vascular muscle (Harris et al., 1989; Komas et al., 1991b) and that in intestinal smooth muscle they also decreased the methacholine-induced maximum contraction more than the other PDE inhibitors (Tomkinson and Raeburn, 1996) .
Moreover, it has been suggested that PDE V is a major cGMP-hydrolyzing enzyme and that the activity of PDE V is mediated by protein kinase G or myosin phosphatase in vascular or uterine smooth muscle cells (Rybalkin et al., 2002) .
However, it has been reported that the vasorelaxant action of amrinone, a PDE III inhibitor, dose not involve cyclic nucleotides (van der Zypp et al., 2000) . Moreover, we reported that papaverine, a nonselective PDE inhibitor, inhibits vascular smooth muscle contraction mainly by increasing cAMP and/or cGMP levels as a result of its inhibition of PDE, but that it acts mainly by inhibiting mitochondrial respiration in ileal smooth muscle (Kaneda et al., 1998) . Therefore, the relationship between PDE inhibitor-induced relaxation and cGMP content in smooth muscle requires further investigation.
The aim of the present study was to clarify the relationship between relaxation and cyclic nucleotide content in carbachol-induced contraction of the longitudinal smooth muscle of the rat ileum which has been inhibited by the selective PDE V inhibitors, MBCQ, zaprinast and dipyridamole.
Methods

Muscle strip preparation and tension measurement
Male rats (Wister strain, 250-300 g; Imamichi Institute for Animal Reproduction, Ibaragi) were bled after stunning, and the ileum quickly removed from each animal. The maintenance of the animals and these experimental procedures were carried out according to the Guidelines for Animal Experimentation as established by the Nippon Veterinary and Animal Science University. The longitudinal muscle layer was stripped from the circular muscle as described by Paton and Aboo Zar (1968) . The muscle strips were about 5-8 mm in width and 15 mm in length. The longitudinal muscle strips were incubated with physiological salt solution (PSS) containing (in mM) 136.8 NaCl, 5.4 KCl, 2.5 CaCl2, 1.0 MgCl2, 11.9 NaHCO3 and 5.5 glucose. The PSS was aerated with 95% O2 and 5% CO2 to adjust to pH 7.2 and maintained at 37°C.
Muscle tension was recorded isometrically. One end of each strip was tied to a glass holder and the other end was connected by a silk thread to a strain-gauge transducer (TB-611T; Nihon Kohden, Tokyo) in an organ bath containing PSS with a resting tension of 1 g. The muscle strips were equilibrated for 30 min to obtain a stable level of contraction induced by 65 mM KCl.
Assay of cGMP or cAMP content
The cGMP or cAMP content in the muscle strips was measured by enzyme immunoassay.
After incubation of the strips with either MBCQ, zaprinast or dipyridamole for 10 min in the presence of carbachol (10 µM), the strips were rapidly frozen in liquid nitrogen and stored at -80°C until they were homogenized in 6% trichloroacetic acid (0.4 ml). The homogenate was centrifuged at 3000 × g for 15 min and the supernatant washed with 1.5 ml of water-saturated diethylether (× 4). The cGMP or cAMP content of the strips was assayed by using an enzyme immunoassay kit (Amersham Pharmacia Biotech, UK). The cGMP or cAMP content was expressed as femtomole per milligram wet weight.
Chemicals
Chemicals used were zaprinast, dipyridamole, carbachol (Sigma, St. Louis, MO, USA) and 4-[[3,4-(Methylenedioxy)benzyl]amino]-6-chloroquinazoline (MBCQ; BIOMOL Research Laboratories, USA). As MBCQ crystallizes if the concentration of MBCQ exceeds 10 µM in PSS, we used MBCQ at concentrations of 10 µM or less in the present study.
Statistics
Values are expressed as the mean ± S.E.M. and statistical analyses were performed using the Student's t-test. Statistical significance was determined at either P<0.05 or P<0.01 respectively.
Results
Effects of MBCQ, zaprinast and dipyridamole on carbachol-or high K + -induced contraction
When a contractile response induced by 10 µM carbachol (CCh) reached a steady level at about 15-20 min after addition, either one of the PDE V inhibitors was added cumulatively. The threshold concentration of MBCQ for the relaxation of ileum was 0.01 µM and that of either zaprinast or dipyridamole was 0.1 µM. Each of these agents inhibited the CCh-induced contraction in a concentration-dependent manner (Fig. 1) . The inhibitory effect of each addition of these agents took 10 min to reach a steady state level. When a comparison was made of the concentrations of these agents required to produce a 50% relaxation (IC50) of the CCh-induced contraction, MBCQ was 10-20 fold more potent than the other agents (Table 1) . MBCQ, zaprinast or dipyridamole also inhibited the contraction induced by high K + (65 mM KCl added hyperosmotically) in a concentration-dependent manner (Fig. 1) . When compared with the IC50 of high K + -induced contraction, MBCQ was 14-24 fold more potent than the other agents (Table  1) .
Effects of MBCQ, zaprinast and dipyridamole on cGMP and cAMP content
As shown in Table 2 , MBCQ (1 or 10 µM) did not significantly increase the cGMP content of the muscle strips above control in the presence of CCh (10 µM). Both Zaprinast (1, 10 or 100 µM) and dipyridamole (1, 10 or 100 µM) increased the cGMP content in a concentrationdependent manner (Table 2 ). There was a positive correlation between the inhibition of the CCh-induced contraction and the increase in cGMP content elicited by zaprinast (r=0.72, P<0.05) and dipyridamole (r=0.92, P<0.05) (Fig. 2) . However, MBCQ at a concentration which induced a medium-sized relaxation did not significantly increase the cGMP content (Fig. 2) .
Neither MBCQ, zaprinast nor dipyridamole significantly increased the cAMP content above control levels (Table 2) . by 10 µM carbachol ( , CCh) or high K + ( , 65 mM KCl) in rat ileal smooth muscle. Preparations were precontracted with CCh or high K + , and then these agents were added cumulatively. The maximum contraction induced by either 10 µM CCh or 65 mM KCl in the absence of these agents was taken as 100%. Each point represents the mean of 7-14 preparations. Vertical bars indicate the S.E.M.
Discussion
PDE plays a major role in the regulation of the intracellular concentrations of cAMP and cGMP (Appleman and Terasaki, 1975) . PDEs are classified into several families (Beavo, 1995; Fawcett et al., 2000; Yuasa et al., 2000) and selective PDE inhibitors have been found (Beavo and Reifsnyder, 1990) . Additionally, PDE V inhibitors are effective in the treatment of male erectile dysfunction and stenocardia.
In the present study, MBCQ, zaprinast and dipyridamole inhibited the CCh-induced contraction in a concentration-dependent manner with maximum inhibitions above 70% (Fig. 1) . However, a comparison of the IC50 of these agents indicated that MBCQ is 14-to 20-fold more potent than zaprinast or dipyridamole in causing relaxation of the CCh-induced contraction (Table 1) . Moreover, in rat ileal smooth muscle, MBCQ, zaprinast and dipyridamole inhibited both the high K + and the CCh-induced contractions to a similar extent ( Fig. 1 and Table 1 ). Zaprinast (1-100 µM) and dipyridamole (1-100 µM) both increased the cGMP content of the muscle strips in a concentration-dependent manner, however MBCQ (1, 10 µM) did not significantly increase the cGMP content above control levels in the presence of CCh (Table 2) . Moreover, there was a positive correlation between the inhibition of the CCh-induced contraction and the increase in cGMP content elicited by both zaprinast and dipyridamole, respectively (zaprinast: r=0.72, P<0.05; dipyridamole: r=0.92, P<0.05, Fig. 2 ). However, MBCQ at a concentration which induced a medium-sized relaxation did not significantly increase the cGMP content (Fig. 2) . One of the reasons that MBCQ did not increase cGMP content is thought to be due to the absence of PDE V in smooth muscle cells of the rat ileum. PDE V has been isolated from vascular smooth muscle (Ahn et al., 1989; Ivorra et al., 1992; Komas et al., 1991a) , tracheal smooth muscle (Burns et al., 1994) or urinary smooth muscle (Qiu et al., 2001) and in each case the activity of the enzyme was inhibited by selective PDE V inhibitors. There has been no evidence reported that PDE V was isolated from ileal smooth muscle. However, in the present study, the widely used PDE V inhibitors, zaprinast and dipyridamole, both increased the cGMP content in rat ileal smooth muscle. These data suggest that PDE V is present in this preparation and that the MBCQ induced-relaxation does not involve the cGMP pathway in rat ileal smooth muscle. Furthermore, the reason that MBCQ did not increase the cGMP content in rat ileal smooth muscle may relate to the localization of PDE V in rat ileal smooth muscle cells. While we have not investigated this possibility, zaprinast and dipyridamole both increased the cGMP content in rat ileal smooth muscle. Therefore, it is unlikely that PDE V is compartmentalized in rat ileal smooth muscle cells. MBCQ, zaprinast and dipyridamole did not significantly increase the cAMP content above control levels in the ileal smooth muscle strips (Table 2 ). This result is consistent with the review that PDE hydrolyzes cGMP specifically (Beavo, 1995) . Therefore, it is thought that the relaxation induced by MBCQ, zaprinast or dipyridamole is not due to an increase of cAMP content in rat ileal smooth muscle. Recently, it was reported that the vasorelaxant action of amrinone, a PDE III inhibitor, did not involve cyclic nucleotides in the rat aorta (van der Zypp et al., 2000) . Moreover, we reported that papaverine, a nonselective PDE inhibitor, inhibits muscle contraction mainly by increasing cAMP and/or cGMP levels due to inhibition of PDE in vascular smooth muscle, but mainly by inhibiting mitochondrial respiration in ileal smooth muscle (Kaneda et al., 1998) . It has been reported that in the porcine aorta, MBCQ inhibited the activity of PDE V and relaxed the prostaglandin F2α-induced contraction (Takase et al., 1994) . Sampson et al. (2001) reported that in the rat mesenteric artery, MBCQ relaxed phenylephrine-induced contractions in a concentration-dependent manner and ODQ, a soluble guanylyl cyclase inhibitor, significantly inhibited the MBCQ-induced relaxation. These reports would suggest that the inhibition of CCh-induced contraction by MBCQ may not involve cyclic nucleotides in the rat ileum and that the mechanisms involved in MBCQ-induced relaxation differ in different organs.
It has been reported that cyclic nucleotide-related agents inhibit receptor agonist-induced contraction with a decrease in intracellular calcium ([Ca 2+ ]i) levels (Karaki et al., 1988; Kwon et al., 1993; Tajimi et al., 1995) . However, these studies showed that cyclic nucleotide-related agents inhibited muscle contraction more than they did the [Ca 2+ ]i levels in a high K + stimulated state in a variety of smooth muscle preparations. We have observed that MBCQ inhibited the high K + -induced muscle contraction and [Ca 2+ ]i levels to the same extent in the guinea-pig urinary bladder (unpublished data). This data would suggest that the mechanism of MBCQ-induced relaxation may not be related to the cyclic nucleotide pathway, although this needs further investigation.
In summary, it is suggested that the inhibition of the CCh-induced contraction of the rat ileal smooth muscle preparations by zaprinast and dipyridamole involves an increase in cGMP content via inhibition of PDE V. However the inhibition of CCh-induced contraction by MBCQ does not involve cyclic nucleotides in rat ileal smooth muscle.
